Oncoloxía médica
Servizo
Clínica Universitaria de Navarra
Pamplona, EspañaPublicacións en colaboración con investigadores/as de Clínica Universitaria de Navarra (9)
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology
2019
-
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)
Scientific Reports
-
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Scientific Reports, Vol. 9, Núm. 1
2016
-
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1237-1242
2011
-
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)
Investigational New Drugs, Vol. 29, Núm. 5, pp. 1038-1044
2010
-
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: A phase 2 study (SOGUG-02-06)
The Lancet Oncology, Vol. 11, Núm. 4, pp. 350-357
-
Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection
Journal of Virology, Vol. 84, Núm. 1, pp. 475-481
2003
1985
-
Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma: Preliminary results
American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 8, Núm. 3, pp. 200-209